替罗非班联合神经介入治疗对急性脑梗死患者神经功能的影响

Yongfei Jiang, Lesheng Wang, Wenze Li
{"title":"替罗非班联合神经介入治疗对急性脑梗死患者神经功能的影响","authors":"Yongfei Jiang, Lesheng Wang, Wenze Li","doi":"10.26689/cnr.v1i2.5378","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the effect of tirofiban combined with neurointerventional therapy on neurological function of patients with acute cerebral infarction. Methods: 70 patients with acute cerebral infarction admitted between January 2022 and January 2023 were selected as research objects, and patients were divided into control group (neurological interventional therapy) and experimental group (tirofiban combined with neurointerventional therapy) according to the computerized grouping method. The treatment outcomes of both groups were compared. Results: The efficacy of the treatment in the experimental group was 94.9%, which was significantly higher that of the control group control group at 77.14% (P < 0.05). Before treatment, there was no difference in the National Institutes of Health Stroke Scale and Barthel Index between the control group and the experimental group (P < 0.05); after treatment, the NIHSS score of the experimental group was lower than that of the control group, and the BI score was higher than that of the control group (P < 0.05). Before treatment, there was no difference in the levels of high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) between the control group and the experimental group (P < 0.05); after treatment, the levels of hs-CRP and NSE in the experimental group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of carbon monoxide (CO), endothelin (ET), nerve growth factor (NGF), and myelin basic protein (MBP) between the control group and the experimental group (P < 0.05); after treatment, the levels of CO and NGF in the experimental group were higher than those in the control group, and the levels of ET and MBP were lower than those in the control group, with statistical significance (P < 0.05). Conclusion: Tirofiban combined with neurointervention is effective in treating acute cerebral infarction. It can not only control the development of the disease, but also improve the patients’ neurological function and the quality of life.","PeriodicalId":87465,"journal":{"name":"Clinical neuroscience research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Tirofiban Combined with Neurointerventional Therapy on Neurological Function of Patients with Acute Cerebral Infarction\",\"authors\":\"Yongfei Jiang, Lesheng Wang, Wenze Li\",\"doi\":\"10.26689/cnr.v1i2.5378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To analyze the effect of tirofiban combined with neurointerventional therapy on neurological function of patients with acute cerebral infarction. Methods: 70 patients with acute cerebral infarction admitted between January 2022 and January 2023 were selected as research objects, and patients were divided into control group (neurological interventional therapy) and experimental group (tirofiban combined with neurointerventional therapy) according to the computerized grouping method. The treatment outcomes of both groups were compared. Results: The efficacy of the treatment in the experimental group was 94.9%, which was significantly higher that of the control group control group at 77.14% (P < 0.05). Before treatment, there was no difference in the National Institutes of Health Stroke Scale and Barthel Index between the control group and the experimental group (P < 0.05); after treatment, the NIHSS score of the experimental group was lower than that of the control group, and the BI score was higher than that of the control group (P < 0.05). Before treatment, there was no difference in the levels of high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) between the control group and the experimental group (P < 0.05); after treatment, the levels of hs-CRP and NSE in the experimental group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of carbon monoxide (CO), endothelin (ET), nerve growth factor (NGF), and myelin basic protein (MBP) between the control group and the experimental group (P < 0.05); after treatment, the levels of CO and NGF in the experimental group were higher than those in the control group, and the levels of ET and MBP were lower than those in the control group, with statistical significance (P < 0.05). Conclusion: Tirofiban combined with neurointervention is effective in treating acute cerebral infarction. It can not only control the development of the disease, but also improve the patients’ neurological function and the quality of life.\",\"PeriodicalId\":87465,\"journal\":{\"name\":\"Clinical neuroscience research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical neuroscience research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26689/cnr.v1i2.5378\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical neuroscience research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/cnr.v1i2.5378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:分析替罗非班联合神经介入治疗对急性脑梗死患者神经功能的影响。方法:选择2022年1月至2023年1月收治的急性脑梗死患者70例作为研究对象,按照计算机化分组方法将患者分为对照组(神经介入治疗)和实验组(替罗非班联合神经介入治疗)。比较两组患者的治疗效果。结果:试验组治疗有效率为94.9%,显著高于对照组77.14% (P <0.05)。治疗前,对照组与实验组卒中量表及Barthel指数比较,差异无统计学意义(P <0.05);治疗后,实验组NIHSS评分低于对照组,BI评分高于对照组(P <0.05)。治疗前,对照组与试验组高敏感c反应蛋白(hs-CRP)、神经元特异性烯醇化酶(NSE)水平比较,差异均无统计学意义(P <0.05);治疗后,实验组hs-CRP、NSE水平均低于对照组(P <0.05)。治疗前,对照组与实验组的一氧化碳(CO)、内皮素(ET)、神经生长因子(NGF)、髓鞘碱性蛋白(MBP)水平差异无统计学意义(P <0.05);治疗后,实验组CO、NGF水平均高于对照组,ET、MBP水平均低于对照组,差异均有统计学意义(P <0.05)。结论:替罗非班联合神经干预治疗急性脑梗死疗效显著。不仅可以控制疾病的发展,还可以改善患者的神经功能和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of Tirofiban Combined with Neurointerventional Therapy on Neurological Function of Patients with Acute Cerebral Infarction
Objective: To analyze the effect of tirofiban combined with neurointerventional therapy on neurological function of patients with acute cerebral infarction. Methods: 70 patients with acute cerebral infarction admitted between January 2022 and January 2023 were selected as research objects, and patients were divided into control group (neurological interventional therapy) and experimental group (tirofiban combined with neurointerventional therapy) according to the computerized grouping method. The treatment outcomes of both groups were compared. Results: The efficacy of the treatment in the experimental group was 94.9%, which was significantly higher that of the control group control group at 77.14% (P < 0.05). Before treatment, there was no difference in the National Institutes of Health Stroke Scale and Barthel Index between the control group and the experimental group (P < 0.05); after treatment, the NIHSS score of the experimental group was lower than that of the control group, and the BI score was higher than that of the control group (P < 0.05). Before treatment, there was no difference in the levels of high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) between the control group and the experimental group (P < 0.05); after treatment, the levels of hs-CRP and NSE in the experimental group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of carbon monoxide (CO), endothelin (ET), nerve growth factor (NGF), and myelin basic protein (MBP) between the control group and the experimental group (P < 0.05); after treatment, the levels of CO and NGF in the experimental group were higher than those in the control group, and the levels of ET and MBP were lower than those in the control group, with statistical significance (P < 0.05). Conclusion: Tirofiban combined with neurointervention is effective in treating acute cerebral infarction. It can not only control the development of the disease, but also improve the patients’ neurological function and the quality of life.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信